Home » Lannett Reaches Special Protocol Assessment Agreement With FDA for Cocaine HCl Phase III Trial
Lannett Reaches Special Protocol Assessment Agreement With FDA for Cocaine HCl Phase III Trial
Lannett Company announced that it has reached agreement with the FDA on a Special Protocol Assessment (SPA), regarding the design of a Phase III study of the company’s Cocaine HCl topical solution product, C-Topical.
MarketWatch
MarketWatch
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May